Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer

Dr Pedro Oliveira, consultant histopathologist, The Christie NHS Foundation Trust. No conflicts of interest declared.

Dr Sanjay Popat, consultant medical oncologist, The Royal Marsden NHS Foundation Trust and reader, Imperial College London, declaration of interests: reimbursed consultant to AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly, Guardant Health, MSD, Novartis, Pfizer, Roche and Takeda.

Prof Siow Ming Lee, professor of medical oncology, University College London and consultant medical oncologist, University College London Hospitals NHS Foundation Trust. No conflicts of interest declared.

Dr Philippe Taniere, consultant histopathologist, University Hospitals Birmingham NHS Foundation Trust and honorary senior lecturer, University of Birmingham. Declaration of interests: received fees for giving lectures or being part of advisory board meetings by the following companies: Roche diagnostics, Qiagen, AstraZeneca, Roche, Boehringer, Lilly, Pfizer, Novartis, MSD and BMS. The NHS laboratory he leads has a contract with AstraZeneca; AstraZeneca supports epidermal growth factor receptor (EGFR) plasma testing for any UK patient; contract does not require a specific technology or platform. Has been an advisor of the study by PHG foundation on circulating tumour DNA (ctDNA) testing in lung cancer (recently published).

Dr Alistair Reid, consultant clinical scientist, Liverpool Clinical Laboratories and honorary senior lecturer, Imperial College London. No conflicts of interest declared.